What to do when you plateau on Wegovy

Is this plateau actually a problem, or is your body doing something expected?

The frustration is real. You started Wegovy, the weight moved, and now it has stopped — and nothing obvious has changed. That feeling of stalling after real progress is one of the most demoralising parts of weight management, and it is worth being honest about how common it is before jumping to conclusions.

Plateaus are a physiological response, not a treatment failure. As body weight falls, resting metabolic rate drops too, a smaller body simply burns fewer calories at rest. The result is that a calorie deficit that produced steady loss three months ago may now be roughly in balance. Whether a stall is a normal phase or a sign something needs reviewing depends on several factors: how long it has lasted, what dose you are on, and what your diet and activity look like right now.

A true plateau is generally defined as four or more weeks without any measurable change in weight, despite no obvious increase in food intake. A single week of no movement, or a brief regain after a salty meal or a disrupted sleep pattern, is not a plateau, it is noise. Before changing anything, it is worth reading about what a Wegovy plateau involves and why it happens so you can approach the next steps with a clearer picture. Most people find that precision here reveals something actionable.

What lifestyle factors most often drive a stall, and how to address them?

Semaglutide reduces appetite significantly, but it does not override a diet that has crept upward in calorie density without you noticing. Highly processed foods, alcohol and liquid calories are the most common culprits, partly because they bypass the gastric-emptying effect that makes Wegovy effective. Prioritising protein (aiming for roughly 1.2–1.6g per kilogram of body weight) helps preserve lean mass and keeps hunger lower between meals, which matters more as the dose plateaus.

Strength exercise is the other underused lever. Cardio burns calories in the session; resistance training shifts what your body does with calories over the following 24–48 hours and protects muscle as fat is lost. The timeline for Wegovy's full effect spans many months, and building muscle during that window pays dividends later. NHS guidance on weight management consistently highlights physical activity as a core component alongside any medicine.

Sleep and stress are less obvious but well-documented. Poor sleep raises ghrelin (the hunger hormone) and blunts the GLP-1 effect; chronic stress raises cortisol, which promotes fat retention particularly around the abdomen. Neither is easily fixed, but identifying which is a factor points toward what to work on first. The full Wegovy overview covers how the medicine interacts with these biological systems.

When should you talk to your prescriber about the plateau?

There are specific circumstances where a clinical conversation should happen rather than a prolonged period of self-adjustment. If you have been on Wegovy for six months or more at the highest dose you have tolerated and weight has not moved in eight or more weeks despite genuine lifestyle effort, that is a conversation worth having. NICE guidance on semaglutide notes that continuing treatment should be reviewed if less than 5% weight loss has occurred after six months on the maintenance dose.

If you are not yet on the 2.4mg maintenance dose, your prescriber may assess whether moving to the next step is appropriate given your current response and tolerability. Dose changes are a clinical decision; do not adjust timing or frequency without guidance, and refer to your Patient Information Leaflet for the specifics of your current pen. The considerations around sourcing Wegovy from a regulated pharmacy are relevant here too, since treatment continuity and dose reviews depend on a provider who actually reviews each prescription.

A prescriber may also consider whether a different medicine is more appropriate. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity. That is not a reason to switch without clinical input, but it is a factual option worth exploring through a proper consultation. You can speak to our prescribers about whether your current treatment plan is still the right one, or whether there is a better path forward.

What should you actually do this week?

Start with the basics before escalating to clinical changes. Log food honestly for seven days, not to restrict further, but to spot where calories have drifted. Check your injection technique: the pen should go into a fatty area of the abdomen, thigh or upper arm, rotated each week. Correct storage matters too; a pen that has been out of the fridge beyond the window stated in your leaflet may not be fully effective, though the exact room-temperature limit varies by product and you should always check the leaflet rather than rely on general guidance online.

Add one session of resistance exercise each week if you are not already doing any. Improve sleep by one hour if you are currently under seven. These are not dramatic changes, but combined they meaningfully shift the conditions under which semaglutide operates. The practical checklist for a Wegovy plateau covers these points in more detail.

If you have done all of that for four weeks and nothing has moved, that is the point to contact your prescriber, not to troubleshoot alone. Our clinical team reviews every repeat order and is available for aftercare questions seven days a week. A plateau is not the end of the road; it is a signal that the approach needs refining, and that is exactly what clinical oversight is for. For broader context on weight-loss treatment options, including how different medicines compare, the overview is a useful starting point.